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ABSTRACT  
Reactive oxygen species (ROS) oxidise nucleotide triphosphate pools (e.g., 8-
oxodGTP), which may kill cells if incorporated into DNA. Whether cancers avoid 
poisoning from oxidised nucleotides by preventing incorporation via the oxidised 
purine diphosphatase MTH1 remains under debate. Also, little is known about DNA 
polymerases incorporating oxidised nucleotides in cells or how oxidised nucleotides in 
DNA become toxic. We show replacement of one of the main DNA replicases in human 
cells, DNA polymerase delta (Pol δ), to an error-prone variant allows increased 8-oxodG 
accumulation into DNA following treatment with the MTH1 inhibitor (MTH1i) TH588. The 
resulting elevated genomic 8-oxodG correlates with increased cytotoxicity of TH588. 
Interestingly, no substantial perturbation of replication fork progression is observed, 
but rather mitotic progression is impaired and mitotic DNA synthesis triggered. 
Reducing mitotic arrest by reversin treatment prevents accumulation of genomic 8-
oxodG and reduces cytotoxicity of TH588, in line with the notion that mitotic arrest is 
required for ROS build-up and oxidation of the nucleotide pool. Furthermore, we 
demonstrate delayed mitosis and increased mitotic cell death following TH588 
treatment in cells expressing the error-prone Pol δ variant, which is not observed 
following treatments with anti-mitotic agents, thus linking incorporation of oxidised 
nucleotides and disturbed mitotic progression.  
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INTRODUCTION 
Oxygen metabolism is critical for many cellular processes, and it is established that reactive 
oxygen species (ROS) can be both beneficial and deleterious to cells. Loss of balanced redox 
homeostasis and/or ROS may have a role in the etiology of many diseases, including cancer, 
cardiovascular disease, hypertension, inflammatory diseases (e.g., atherosclerosis, 
rheumatoid arthritis), ischemia-reperfusion injury, diabetes mellitus, neurodegenerative 
diseases, and ageing (1,2). ROS causes oxidative DNA damage, either directly in the DNA, 
which then can be repaired by the 8-oxoguanine glycosylase OGG1, or by oxidising the 
nucleobases in the free deoxynucleoside triphosphate (dNTP) pool. The human MutT 
homologue 1 (MTH1) protein, an oxidised purine diphosphatase, is important to prevent 
oxidised dNTPs, such as 8-oxodGTP and 2-OHdATP, from being incorporated into DNA (3,4). 
   Previously, we and others showed that the normally non-essential MTH1 enzyme is required 
for survival of cancer cells (5-8), while others have ruled out MTH1 as an anti-cancer target 
altogether (9-11). We showed that the wild-type MTH1 or bacterial MutT protein can rescue 8-
oxodGTP incorporation and toxicity generated following MTH1 siRNA depletion and treatment 
with the MTH1 inhibitor (MTH1i) TH588 (6,12), consistent with incorporation of 8-oxodGTP into 
DNA having toxic effects. MTH1i TH588 and the best-in-class analogue, the clinical candidate 
TH1579 (karonudib), possess dual pharmacology, inhibiting microtubule polymerisation 
directly in addition to inhibiting MTH1 (10) and the MTH1 protein itself is required for mitosis 
and binds tubulin directly (Gad et al., submitted), which altogether are complicating the 
understanding of what effects are generated through mitosis or through incorporation of 8-
oxodGTP.   
   Pol δ is a main DNA polymerase involved in lagging strand synthesis as well as being the 
main DNA polymerase for repair or break-induced replication (13). Emerging data also 
suggests Pol δ is the main DNA polymerase for leading strand synthesis (14). Unlike trans-
lesion synthesis polymerases, Pol δ has less tolerance to replicate across lesions and only 
accepts very slight base modifications to be able to polymerise DNA with modified nucleotide 
substrates. Hence, 8-oxodGTP is likely a poor substrate for Pol δ in cells. To investigate the 
author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/573931doi: bioRxiv preprint 
  
 4 
cellular fate of 8-oxodGTP, we here use a recently reported protein-replacement system 
allowing the replacement of endogenous Pol δ with an error-prone variant (15). Here, we report 
increased incorporation of 8-oxodGTP when cells express the error prone variant are exposed 
to MTH1i TH588 enabling us to use this model to increase our understanding of the role of 
genomic 8-oxodG lesions. These experiments are highly relevant for cancer treatment as 
MTH1i TH1579 (karonudib) is currently evaluated in clinical trials for anti-cancer efficacy. 
 
MATERIALS AND METHODS 
Cell culture 
All cell lines were cultured at 37°C in 5% CO2. U2OS cells (ATCC) were cultured in DMEM 
media supplemented with 10% FBS and Penicillin Streptomycin (100 U/ml), A2780 Pol δ 
replacement cells (15) were cultured in DMEM with 5% low TET FBS and 100 µg/mL G418, 
10 µg/mL Blasticidin and 1 µg/mL Puromycin. All cell culture reagents were from Gibco/Thermo 
Fisher.  
 
Compounds 
The following chemical inhibitors were used: CENP-E inhibitor (GSK923295, SelleckChem), 
Vincristine sulfate (Sigma Aldrich), Paclitaxel (Sigma Aldrich), Reversine (Axon MedChem), 
RO3306 (SelleckChem), Aphidicolin (Sigma Aldrich). TH588(6) was synthesized in house and  
prepared as previously reported.  
 
Antibodies 
The following antibodies were used: mouse anti beta-Actin (ab6276, Abcam), mouse anti-ATM 
pS1981 (sc47739, Santa Cruz Biotech), rabbit anti-ATR phospho S428 (ab178407, Abcam), 
rabbit anti-Cdk2 phospho-T14/T15 (Santa Cruz, sc28435-R), rabbit anti-Chk1 phospho S345 
(#2341, Cell Signaling), mouse anti-Chk1 (#2360, Cell Signaling), rabbit anti-GAPDH (sc-
25778, Santa Cruz), mouse anti-H2A.X phospho S139 (05-636, Millipore), mouse anti-Histone 
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H3 phospho-S10 (H3-pS10; ab14955, Abcam), rabbit anti-Histone H3 (#4318, Cell Signaling), 
rabbit anti-MTH1 (NB100-109, Novus Biologicals), rabbit anti-p21 (H164, Santa Cruz Biotech), 
rabbit anti-cleaved PARP (#9541, Cell Signaling), mouse anti-PLK1 (Millipore, #5844), mouse 
anti alpha-Tubulin, mouse anti-DNA Pol δ catalytic subunit (p125) (ab10362, Abcam). 
 
Generation of H2B-GFP cell lines 
The H2B-GFP vector was constructed by amplifying H2B from the H2B-RFP pENTR1A vector 
(Addgene # 22525) by PCR and subcloning the product into the pENTR1A-GFP-N2 vector 
(Addgene # 9364) at the HindIII and BamH1 restriction sites. The H2B-pENTR1A-GFP-N2 
vector was verified by sequencing and transferred into the pLenti-CMV-Blast and pLenti-CMV-
Hygro vectors using LR clonase (Invitrogen). H2B-RFP in pENTR1A (w507-1) and pENTR1A-
GFP-N2 (FR1) were gifts from Eric Campeau and Paul Kaufman (Addgene plasmids # 22525 
and # 19364). H2B-GFP plasmids were transduced using lentivirus infections. 
 
Western blot 
Cells were washed with 1x PBS and scraped in lysis buffer (50 mM Tris-HCl pH 8, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS , 1x protease inhibitor cocktail (Thermo), and 
1x Halts phosphatase inhibitor cocktail (Thermo)). Samples were incubated on ice for 30 min 
with occasional vortexing before centrifugation to pellet insoluble material. Protein 
concentration was measured using BCA Assay (ThermoFisher) before preparation in Laemmli 
Sample Buffer (Bio-Rad) containing 355 mM final concentration 2-mercaptoethanol, and 
samples were denatured at 95°C for 5 min. Samples were run on 4-12% SDS-PAGE gels 
(Mini-Protean TGX Precast gel, Bio-Rad) and subsequently transferred to nitrocellulose 
membranes using the Trans-Blot Turbo instrument (Bio-Rad). Membranes were stained with 
Ponceau S and blocked in Odyssey TBS Blocking Buffer (Li-Cor) for 1 h. Antibodies were 
diluted in Odyssey TBS Blocking Buffer and incubated overnight at 4°C. Membranes were 
washed with TBS supplemented with Tween-20 (0.1%) before incubation with secondary 
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antibodies (IRDye 800CW and IRDye 680LT) diluted in TBS-Tween before further washes and 
imaging using the LI-COR Odyssey Fc Imaging system.  
 
Cell viability assay 
Cell viability was assessed using the resazurin assay. In the case of Pol δ replacement cells, 
prior to the cell viability assay, cells were seeded in 6-well plates and cultured in medium 
supplemented with 10 ng/ml doxycycline for 3 days before trypsinization and re-seeding; 
doxycycline supplementation was maintained for the remainder of the assay. For the cell 
viability assay, typically 1500 cells per well were seeded in 90 µl media in 96-well plates, and 
the following day, the drug to be tested was serially diluted in media and 10 µl 10x drug dilution 
added to the desired well. Following 3 days treatment, viable cells were measured using 
resazurin (Sigma Aldrich; cat no. R7017), as described previously (6) Measurements for each 
well were normalized to control wells (cells with DMSO, 100% viable control; medium with 
DMSO, 0% viable control) and analyzed using four-parameter logistic model in Prism 8 
(GraphPad Software). 
 
DNA fiber technique 
Cells were seeded in 6-well plates, typically 200 000 – 300 000 per well, to reach 70% 
confluency on day of experiment. For the time-course analysis in U2OS cells, 5 µM TH588 
was added 8, 4, and 1 hour before labeling or directly with labeling, and an 8 hour DMSO 
control was also included. For experiment with the Pol δ replacement cells, cells cultured in 10 
ng/ml doxycycline for 4 days were treated with 1 µM TH588 or mock treated with DMSO for 
the indicated times. Treatment was followed by pulse-labelling for 20 minutes with 25 µM 5-
Chloro-2′-deoxyuridine (CldU, Sigma) and then 20 minutes with 250 µM 5-Iodo-2′-deoxyuridine 
(IdU, Sigma). The inhibitor and mock treatment was present during labelling. Cells were 
harvested and resuspended in ice-cold PBS. Lysing of cells were performed by incubating a 
drop of cell suspension together with spreading buffer (200 mM Tris–HCl, pH 7.4, 50 mM 
EDTA and 0.5% SDS) on SuperFrost objective glass (Thermo Scientific). DNA fibers were 
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spread by tilting the glass slides allowing the cell lysate to slowly run down the slide. For 
immunodetection of CldU and IdU, acid treated fibers (2.5 M HCl for 1 hour) were stained with 
monoclonal rat anti-BrdU (1:500) (Clone BU1/75 (ICR1) (AbD Serotec) and monoclonal mouse 
anti-BrdU (1:500) (Clone B44, 347580 (BD Biosciences)) respectively for 1 hour in 37°C. This 
was followed by incubation with Alexa555-conjugated anti-rat and Alexa488-conjugated anti-
mouse (Molecular Probes). DNA fibers were studied in a LSM780 confocal microscope using 
a 64x oil objective and lengths of CldU and IdU tracks were measured using the ImageJ 
software (http://fiji.sc/Fiji), 50-100 replication tracks were scored for each condition. 
 
Mitotic DNA replication 
U2OS cells were seeded on coverslips one day before. The next day the cells were incubated 
for 16h with the CDK inhibitor RO3306 (9µM) alone or in combination with either 0.4µM 
Aphidicolin (APH), 5µM TH588, or 500nM TH1579. Afterwards the cells were washed with pre-
warmed PBS 4-5 times and within 5 minutes to release the cells into mitosis and incubated 
with fresh media containing 10µM EdU for 30min at 37ºC. Fixation and permeabilisation was 
done simultaneously with PTEMF solution for 20min at room temperature. Blocking was done 
in 3% BSA in PBST 0.5% for 1h at room temperature followed by EdU detection with the Click-
iT EdU reaction kit (Thermo Scientific), following the manufacturer’s instructions. The nucleus 
was visualized with DAPI. For labelling of mitotic cells anti-H3pS10 primary antibody was used. 
 
High content microscopy 
Pol δ replacement cells were first cultured with media supplemented with 10 ng/ml doxycycline 
for 3 days before seeding at 10 000 cells per well in black, clear-bottomed 96-well plates (BD 
Falcon). The following day, if labelling S-phase cells, cells were pulse-labelled with 10 µM EdU 
for 20 minutes prior to fixation in 4% paraformaldehyde in PBS (Santa Cruz) containing 0.5% 
Triton X-100 for 15 min. Wells were washed with PBS before permeabilisation in 0.3% Triton 
X-100. For detection of EdU labelled cells, a click reaction mix was assembled in PBS 
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containing 2.5 mM copper (II) sulphate, 10 mM ascorbic acid and 2 µM ATTO-488 azide 
fluorophore (ATTO-TEC), which was added to wells and incubated in the dark for 30 minutes. 
Wells were washed in PBS, cell nuclei stained with 1 µg/ml DAPI for 10 min, and further 
washed in PBS prior to imaging. Plates were imaged on an ImageXpress high-throughput 
microscope (Molecular Devices) with a 20x objective. Images were analyzed (nuclei counting, 
DAPI and EdU nuclear intensity measurements) with CellProfiler (Broad Institute) and data 
handled in Excel and plotted in Prism6. 
 
Modified comet assay 
Cells were seed in 6-well plates at a density of 150-200 000 cells per well and either on the 
same day (suspension cells) or the day after (adherent cells) treated for 24h with compound 
or DMSO control . Cells were harvested by trypsinization, washed once in PBS and 
resuspended in 300µl PBS. The suspension (100 µl) was mixed with 500 µl 1.2% low melting 
point agarose at 37°C and the mixture were added to agarose coated slides and a coverslip 
was added on top. The slides were solidified on ice and lysed O/N at 4°C in Lysis buffer (2.5 
M NaCl, 100 mM EDTA, 10 mM Tris, 10% DMSO, 1% Triton X100). Samples were washed 3 
times in Enzyme buffer (40 mM HEPES, 0.1 M KCl, 0.5 mM EDTA, 0.2 mg/ml BSA, pH 8.0) 
and treated with hOGG1 enzyme (2 µg/ml) or buffer alone for 45 min at 37°C. hOGG1 was 
expressed in E. coli and purified as previously described (Gad et al 2014). Slides were 
transferred to Alkaline Electrophoresis buffer (300 mM NaOH, 10 mM EDTA) for 30 min and 
electrophoresis was performed at 25V, 300 mA for 30 min at 4°C. Samples were washed in 
400 mM Tris pH 7.5 for 45 min. DNA was stained with SybrGOLD and comets were quantified 
with Comet Assay IV software in live video mode. 
 
Time-lapse microscopy 
Cells were seeded in 96-well plates (BD Falcon plate 353376; 5000 cells/well). The day after, 
cells were treated and the time-lapse was initiated after 30 min and images of GFP and 
brightfield channels were acquired every 10 min for 24 h in a Perkin-Elmer ImageXpress 
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instrument. Cells were kept at 37°C in 5% CO2 atmosphere during the entire time-lapse 
experiment. Movie files were assembled in MetaXpress and ImageJ softwares. For each 
condition, images were acquired from two different wells. Individual cells were followed 
manually and scored for defects in mitosis including mitotic slippage/polynucleation (MS/PN), 
micronuclei formation (G1/MN), mitotic slippage (MS) or cell death during mitosis (DiM). The 
time in mitosis was defined as the time from the cell rounding up and condensing the chromatin 
to the end of cytokinesis.  
 
Statistical analysis 
All statistical analysis was performed using Prism 8 (GraphPad software).  
 
RESULTS 
An experimental system to study 8-oxodGTP incorporation into DNA 
Our original model on the role of MTH1 in protecting cancer cells centred upon the mis-
incorporation of oxidised nucleotides, such as 8-oxodGTP, into DNA as the toxic lesion (6). 
More recently, others and ourselves have demonstrated direct action of TH588 on tubulin 
polymerisation and that MTH1 itself has a novel role in mitosis, rendering a more complex 
mechanism of action of TH588 and MTH1 as an anti-cancer target (Gad et al., submitted). With 
this background it is important to understand if 8-oxodG in DNA is a potentially lethal lesion 
and how this is incorporated in cells. To re-examine this model we employed a recently 
reported protein-replacement system that allows the doxycycline-inducible replacement of 
endogenous Pol δ, one of the main DNA replicases in cells, with either a wild type (WT), error-
prone (EP, L606G), proofreading-deficient (PD, D402A), or EP and PD double mutant (DM) 
variant in the ovarian cancer cell line A2780 (Figure 1a). We were particularly interested in the 
EP variant as we reasoned this would increase mis-incorporation of oxidised nucleotides into 
DNA and thus provide a controlled experimental system to study the consequences of TH588-
treatment. Importantly, within the timeline of the experiments performed, replacement of 
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endogenous Pol δ with the Pol δ variants did not significantly reduce cell viability (Figure 1b) 
and had a minimal effect on the proportion of S-phase cells (Figure 1c), with the exception of 
the DM variant, which had a small but significant increase in the proportion of S-phase cells, 
as previously reported (15). To determine whether replacement of Pol δ with the EP variant 
and subsequent TH588 treatment leads to increased genomic 8-oxodG, we employed the 
modified comet assay in which cells embedded in agarose are exposed to recombinant OGG1 
prior to electrophoresis under alkaline conditions. The presence of 8-oxodG in DNA would lead 
to increased OGG1-induced comet tails in the assay. Consistent with our previous reports 
(6,16), TH588 treatment, irrespective of Pol δ status, resulted in increased 8-oxodG in DNA as 
compared to DMSO treated controls (Figure 1d, e). The highest accumulation of genomic 8-
oxodG was observed in the TH588-treated cells expressing the Pol δ EP variant (Figure 1d, 
e), indicating that this reduced-fidelity variant of this replicase mis-incorporates 8-oxodG into 
DNA. Thus, we have an experimental system with which to study the cellular consequences 
of increased mis-incorporation of 8-oxodGTP into DNA. 
 
Increased genomic 8-oxodG in TH588-treated Pol δ EP cells correlates with increased 
toxicity 
The cytotoxic effects of TH588 have been proposed to be independent of targeting MTH1 and 
independent of 8-oxodGTP (9,10,17), while we have shown TH588 cytotoxicity is related to 
ROS and partly rescued by expression of the bacterial 8-oxodGTPase MutT (6,12,18). Here, 
we wanted to use this experimental system to determine the contribution of 8-oxodGTP 
incorporation to the cytotoxicity of TH588. In accordance with the original proposed mechanism 
of action of MTH1 inhibition, replacement of endogenous Pol δ with the EP but not WT variant 
increased TH588-induced cytotoxicity (Figure 2a). Elevated sensitivity was also observed in 
the cells expressing the Pol δ DM but not PD variant (Figure 2a), indicating the increased 
sensitivity was due to the point mutation reducing Pol δ fidelity, i.e. the EP variant. In line with 
this, elevated DNA damage (γH2Ax) and apoptotic (cleaved-PARP) signalling was observed 
in the EP and DM variant expressing cells compared to WT control (Figure 2b). Taken 
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together, this data indicates that incorporation of TH588-induced 8-oxodGTP contributes to 
cell killing. 
 
8-oxodGTP incorporation does not greatly perturb S-phase DNA synthesis 
It is easy to envision that mis-incorporation of 8-oxodGTP would generate replication stress, 
as MTH1 overexpression reduces Ras-induced DNA lesions and counteracts oncogenic stress 
(8,19), and replication stress is associated with oxidative stress in cancer (20) and replication 
difficulties (21,22). Therefore, we wanted to investigate if MTH1 inhibition and resulting 
incorporation of oxidised nucleotides would result in replication stress. To test this we used the 
well-established DNA fibre assay in cells expressing either the Pol δ WT or EP variant treated 
with TH588 for 0-6 hours prior to the assay. Two hours of TH588 treatment resulted in a small, 
but significant, decrease in replication fork speeds regardless of whether cells were expressing 
the WT or EP variant of Pol δ, and this decreased fork speed recovered to DMSO-treated 
control levels following 6 hours TH588 treatment (Figure 3a, b). Notably, expression of the Pol 
δ EP variant did not significantly alter this TH588-induced replication defect compared to WT 
controls (Figure 3a, b). In a parallel set of experiments, the replication stress response was 
also monitored in osteosarcoma U2OS cells treated with TH588, which we have previously 
reported are sensitive to TH588 treatment and accumulate genomic 8-oxodG (6). Similarly, an 
initial small, but significant, decrease in replication fork speeds were observed following TH588 
treatment, but fork speeds quickly recovered to that of the control following longer treatment 
times (Supplemental Figure 1a, b). Consistent with no great perturbation of ongoing DNA 
synthesis, no activation of the intra-S-phase checkpoint kinase Chk1 was observed following 
TH588 treatment, despite the induction of DNA damage signalling at later timepoints 
(Supplemental Figure 1c).   
   Upon DNA damage, replication may proceed downstream of a stalled fork by origin-
independent re-priming, e.g., by PrimPol (23,24), leaving a gap on the nascent DNA strand 
which cannot be detected by the DNA fibre assay (25). To test if gaps are generated along the 
replicating nascent DNA strand, we made use of an in house assay which detects such gaps 
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(26). Briefly, we 3H-thymidine pulse-labelled ongoing forks, and then let these progress from 
the labelled area for different times. By addition of alkaline solution, DNA unwinding takes 
place from the single-stranded ends of the fork or gaps, if present. Hence, as the fork moves 
forward or the gaps are filled, the labelling is removed from the fraction of DNA that becomes 
single-stranded. Using this assay we demonstrate that no gaps are generated behind the fork 
during replication following TH588 treatment, regardless of Pol δ status (Figure 3c). Taken 
together, these data indicate that despite incorporation of oxidised nucleotides, and the 
ultimate cytotoxicity, no substantial, sustained perturbation of ongoing DNA synthesis in S-
phase cells is observed following TH588 treatment. 
 
Treatment with TH588 triggers mitotic DNA replication 
Emerging data shows TH588 and MTH1 siRNA arrest cells in mitosis through interference of 
tubulin dynamics, and in the case of TH588, primarily due to direct inhibition of tubulin 
polymerisation (10) (Gad et al., submitted). The explanation for MTH1i or MTH1 siRNA to fail 
to be toxic in cancer cell lines could be explained by lack of ROS, which is supported by non-
toxic MTH1i becoming toxic in the presence of ROS and also that MTH1 knockout zebrafish 
embryos are sensitive to microinjection of 8-oxodGTP (Gad et al, submitted). It has been 
reported that ROS and oxidative stress are elevated during mitosis and that mitotic arrest itself 
generates ROS (27), with one report linking this to mitophagy (28), and hence MTH1 may have 
a role in hydrolysing oxidised purine nucleotides during mitosis.  Normally, DNA replication is 
completed during the S-phase of the cell cycle. However, under conditions of replication stress, 
such as that generated experimentally by low-dose aphidicolin treatment, it has been 
demonstrated that under-replicated regions are repaired by Pol δ–mediated mitotic DNA 
replication at common fragile sites (29). Since replication stress is often found in cancer (21), 
this may explain how 8-oxodGTP could be specifically incorporated in cancer cells following 
MTH1 siRNA or TH588 treatment, as previously reported. To test if TH588 would induce mitotic 
DNA replication, we synchronized U2OS cells in G2 using the Cdk1 inhibitor RO-3306 together 
with 0.4 µM aphidicolin as a positive control or TH588. Cells were released into mitosis for 30 
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min by washout of the compounds and EdU was added to the media to label newly synthesized 
DNA. As expected, aphidicolin induced EdU foci in mitotic cells and so did TH588 (Figure 4a, 
b), suggesting that mitotic replication is stimulated with this compound. 
 
Spindle assembly checkpoint-mediated mitotic arrest is required for 8-oxodG 
accumulation and toxicity induced by TH588 
Since replication in S phase is not greatly perturbed by TH588 treatment and instead this agent 
triggers mitotic DNA replication, we hypothesised that incorporation of 8-oxodGTP caused by 
TH588 into DNA may be dependent upon mitotic arrest, in order to generate ROS and provide 
time for mitotic DNA synthesis. To test this hypothesis we used an inhibitor to the mitotic kinase 
mps1 (reversine) that prevents the spindle assembly checkpoint (SAC) activation (30) in 
combination with TH588 treatment in U2OS cells. TH588 treatment induces a mitotic arrest 
(Figure 5a), and here we show that this arrest is dependent upon a functional SAC as reversin 
co-treatment ablates this mitotic arrest (Figure 5a). In accordance with our hypothesis, 
reversin treatment also prevents accumulation of TH588-induced genomic 8-oxodG and cell 
death (Figure 5b, c). Thus, this data demonstrates that SAC-dependent mitotic arrest is 
required for accumulation of genomic 8-oxodG and cell death following treatment with TH588.  
 
Delayed mitotic progression in Pol δ EP cells treated with TH588, but not by anti-tubulin 
poisons  
We hypothesised that additional mis-incorporation of oxidised nucleotides prior to, or during, 
mitotic entry could contribute to the mitosis-dependent cell death mechanism we observed. To 
test this we generated H2B-GFP expressing Pol δ replacement cells, and following TH588 
treatment, monitored mitotic progression using live cell microscopy. In doxycycline-induced Pol 
δ WT cells, low-doses of TH588 induced a mitotic arrest, but the majority of cells could proceed 
into anaphase without apparent problems (Figure 6a, b; Movie S1). In contrast, the Pol δ EP 
expressing cells had a prolonged mitotic arrest in the presence of TH588 and underwent mitotic 
catastrophe, either becoming polynucleated or undergoing mitotic cell death (Figure 6a, b; 
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Movie S2). These data suggest that oxidised dNTPs incorporated during mitotic replication 
can result in mitotic catastrophe. 
   To offer an alternative explanation, the mitotic defects induced by TH588 in Pol δ EP but not 
in WT expressing cells could potentially be a consequence of direct induction of ROS by the 
compounds, and Pol δ EP cells being able to incorporate 8-oxodGTP into DNA. Hence the 
effect may be independent of MTH1 inhibition by TH588. To test this, we triggered mitotic 
arrest and ROS using the tubulin poison paclitaxel and followed mitosis using live cell imaging. 
Interestingly, we found no difference in mitotic progression between Pol δ EP and WT 
expressing cells (Figure 7a, b), showing that a mitotic delay by itself without concomitant 
inhibition of MTH1 is insufficient to cause a differential response in Pol δ EP and WT 
expressing cells. To further support that MTH1 inhibition is important for the observed effect, 
Pol δ EP and WT cells were treated with other mitosis-targeted compounds, vincristine or an 
inhibitor to CENP-E, which resulted in no difference in mitotic progression between the two cell 
types (Figure 7c). Taken together, these data indicate that cancer cell death caused by TH588 
is a combinatorial effect due to perturbation of microtubule dynamics and incorporation of 
oxidised nucleotides into the genome. Furthermore, mis-incorporation of oxidised dNTPs may 
alter mitotic progression.  
    
DISCUSSION 
Here, we aimed to explore if and how oxidised dNTPs, incorporated into DNA, are toxic to 
cells. we used a previously established doxycycline-inducible replacement of endogenous Pol 
δ with an error-prone (L606G) variant (15), which we confirm did not greatly alter cell cycle 
progression or overall viability of cells. We demonstrate increased 8-oxodGTP incorporation in 
these cells, providing an experimental system by which to study incorporation of oxidative 
nucleotides into DNA and the resultant cellular consequences. 
   Since Pol δ is a main DNA polymerase one would expect a huge increase in 8-oxodG DNA 
levels and detrimental effects on replication in Pol δ EP cells exposed to MTH1i TH588, which 
we show is not the case. Since we observe minor alterations, and no generation of post-
author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/573931doi: bioRxiv preprint 
  
 15 
replication gaps, we suggest that the overall level of 8-oxodGTP is very low in the S phase of 
the cell cycle making MTH1 function redundant during this phase in unstressed conditions.  
   ROS is known to accumulate throughout the cell cycle, peaking in mitosis, and accordingly 
is induced following extended mitotic arrest (27,28). TH588 causes arrest in mitosis owing to 
a direct effect on tubulin (10) and likely also through disrupting the binding between MTH1 and 
tubulin in cells, resulting in reduced microtubule polymerisation rates (Gad et al., submitted). 
The discussion of the role of MTH1 on tubulin and in mitosis and the role of TH588 binding to 
tubulin is detailed elsewhere (Gad et al., submitted) and not the topic of this report. 
Nonetheless, TH588-induced arrest in mitosis is associated with an increase in ROS likely 
resulting in increased 8-oxodGTP levels in mitosis. Here, we report an increase in mitotic DNA 
replication following treatment with TH588 and also that the incorporation of 8-oxodGTP into 
DNA is dependent on an extended mitotic arrest, as pharmacologically reducing the time in 
mitosis reduced the incorporation of 8-oxodGTP as well as toxicity of TH588 (Figure 5).  
   A highly surprising finding is that Pol δ EP cells show a more pronounced delay in mitosis as 
compared to Pol δ WT cells suggesting incorporation of 8-oxodGTP into DNA is increasing the 
mitotic defect (Figure 6). Understanding how this work mechanistically will be challenging and 
should be addressed in future studies. An alternative explanation is that Pol δ EP cells would 
be prone to generate severe mitotic arrest owing to MTH1 and 8-oxodGTP independent 
effects. We argue this is not the case, as this mitotic arrest is not a phenomena observed 
generally following treatments with microtubule poisons (Figure 7). 
    Here, we propose a suitable model on the mechanism of action of TH588 (Figure 7d). 
TH588 does not lead to substantial obstruction of replication forks in S-phase due to low levels 
of ROS, which is supported by a recent study demonstrating elevated ROS levels in cancer 
cells primarily during G2 and particularly mitosis (27), which may also explain why other MTH1i 
that do not arrest cells in mitosis are non-toxic. ROS are accumulating upon mitotic arrest by 
TH588, mediated through a direct effect on tubulin and potentially also by disrupting MTH1 
mitotic function and preventing the tubulin-MTH1 interaction (Gad et al., submitted). The 
nucleotide pool is oxidised in the presence of ROS in mitosis generating 8-oxodGTP, which is 
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a substrate for MTH1 which prevents mitotic DNA damage. Upon inhibition of MTH1 8-
oxodGTPase activity by TH588, 8-oxodGTP is incorporated into DNA during mitotic replication 
in cancer cells and enhances the mitotic arrest by a mechanism yet to establish.  
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SUPPLEMENTARY DATA 
Supplementary Data consists of one figure and two movies. 
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MAIN FIGURES & LEGENDS 
Figure 1 | An experimental system to study 8-oxodGTP incorporation into DNA. 
a) Pol δ replacement cells (WT, wild type; EP, error-prone; PD, proofreading deficient; DM, EP 
and PD double mutant) were cultured in the presence or absence 10 ng/ml doxycycline for 4 
days and lysates prepared for western blot analysis with the indicated antibodies.  
b) Pol δ replacement cells were cultured in 10 ng/ml doxycycline for 7 days and viable cells 
measured using the resazurin assay. Values were normalized to Pol δ replacement cells 
cultured in the absence of doxycycline. Averages of 3 experiments shown each performed in 
sextuplet, error bars indicate SD.  
c) Pol δ replacement cells were cultured in 10 ng/ml doxycycline for 4 days were labeled with 
10 µM EdU for 20 minutes prior to fixation. S-phase cells were defined at >9 EdU foci per 
nucleus, at least 2000 cells were analysed per well with experiments performed at least with 
duplicate wells. Average of at least 3 independent experiments are plotted, error bars indicate 
SD.  
d, e) Pol δ replacement cells (WT, wild type; EP, error prone) were cultured in 10 ng/ml  
doxycycline for 4 days before treatment with 1 µM TH588 for 24 hours. Genomic levels of 8-
oxo-dG were analysed using the modified comet assay, representative images are shown in 
(d). Fold difference in tail moment comparing OGG1-treated to buffer only control shown in (e). 
At least 200 cells were analysed in 2 independent experiments, horizontal bar indicates the 
median, statistical comparison performed using Mann-Whitney tests (****, p<0.0001). 
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Figure 2 | An error-prone variant of Pol δ sensitizes cells to TH588. 
a) Pol δ replacement cells (WT, wild type; EP, error-prone; PD, proofreading deficient; DM, EP 
and PD double mutant) were cultured in the presence or absence 10 ng/ml doxycycline for 3 
days prior to re-seeding, and 24 hours later, treatment with a dose-response of TH588 in media 
with or without doxycycline. Viable cells were measured following a 3 day treatment. A 
representative of 4 independent experiments is shown, performed in sextuplet, with error bars 
indicating SD. Statistical comparisons performed with a two-way ANOVA ( *, p≤0.05; **, 
p≤0.01; ****, p<0.0001).  
b) Pol δ replacement cells were cultured with doxycycline for 4 days and then treated with 1 
µM TH588 for the indicated times before collection for western blot analysis with the indicated 
antibodies. Representative blot of 2 independent experiments shown.  
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Figure 3 | Incorporation of TH588-induced 8-oxodGTP does not cause sustained 
replication stress in S-phase.  
a, b). Pol δ replacement cells were cultured with doxycycline for 4 days before treatment with 
1 µM TH588 for the indicated time and sequential pulse labeling with CldU and IdU prior to 
preparation and analysis of spread DNA fibres. Representative DNA fibre images are shown 
in (a). Measured fork speeds from two independent experiments are shown in (b), with at least 
200 fibers measured in total. Horizontal pars indicate the median, statistical testing was 
performed using Mann-Whitney tests (ns, not significant; **, p≤0.01) 
c) Alkaline DNA unwinding assay with Pol δ replacement WT or EP cells treated with 10 ng/ml 
doxycycline for 4 days prior to the indicated treatments. Average from 2 independent 
experiments shown, mean values plotted with error bars indicating SD. Caffeine is used as the 
post-replication repair of gaps is caffeine dependent, hence, the detection of gaps can be 
increased with caffeine. 
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Figure 4 | TH588 triggers mitotic replication.  
a, b) U2OS cells were treated with Cdk1 inhibitor RO3306 together with 0.4 µM aphidicolin 
(APH) or 5 µM TH588 for 16 h. Compounds were washed away and cells were released for 30 
min in the presence of 10 µM EdU. EdU was labelled with Alexa-488-azide, mitotic cells with 
an H3-pS10 antibody, and DNA with DAPI. Representative images shown in (a), quantification 
of cells containing mitotic EdU foci shown in (b).   Data shown as mean of >160 cells analysed 
per condition from 2 independent experiments, error bars indicate SD. Statistical test 
performed using Student’s t-test (* p<0.05).  
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Figure 5 | Mitotic arrest required for accumulation of genomic 8-oxodG following 
treatment with TH588.  
a) Quantification of the time in mitosis from the onset of pro-phase until the end of cytokinesis 
in U2OS-H2B-GFP cells treated with 10 µM TH588 and 0.5 µM Reversine for 24 h. Individual 
cells shown from a representative experiment, horizontal line indicates the mean.  
b) Relative tail moment in the modified comet assay of U2OS cells treated with 10 µM TH588 
and 0.5 µM Reversine for 24 h. Data from two independent experiments shown with 400 cells 
analysed in total, horizontal line indicates the median, statistical testing was performed using 
the Mann-Whitney test (****, p<0.001).  
c)  Viability assay of U2OS cells treated with TH588 with or without 0.5 µM Reversine for 72 
h. Mean of 3 independent experiments shown, error bars indicate SD.  
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Figure 6 | Expression of an error-prone variant of Pol δ results in a prolonged mitotic 
arrest and elevated mitotic cell death following TH588 treatment.  
a) Quantification of the time in mitosis from onset of pro-phase until end of cytokinesis. Data 
from two experiments, 50 cells analysed in total, horizontal line indicates the mean. Statistical 
testing performed with unpaired t-test (****p>0.001).  
b) Pol δ replacement-H2B-GFP cells (WT, wild type; EP, error-prone) were treated with 10 
ng/ml doxycyclin for 4 days before treatment with 2.5 µM TH588 and subsequent initiation of 
the time-lapse microscopy after 30 min. Images were acquired every 10 min for 24 h. Individual 
cells were followed manually and scored for defects in mitosis including mitotic 
slippage/polynucleation (MS/PN), micronuclei formation (G1/MN), mitotic slippage (MS) or cell 
death during mitosis (DiM). Representative of two independent experiments shown. 
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Figure 7 | Expression of an error-prone variant of Pol δ does not result in prolonged 
mitotic arrest and elevated mitotic cell death induced by mitotic poisons.  
a) Quantification of the time in mitosis from the onset of pro-phase until the end of cytokinesis 
followed treatment with 2 nM Paclitaxel (PTX). Individual cells shown from a representative 
experiment, horizontal line indicates the mean. Statistical testing performed using unpaired t-
test (ns, not significant).  
b) Time-lapse imaging of Pol δ replacement-H2B-GFP cells induced with 10 ng/ml doxycycline 
for 4 days prior to treatment with 2 nM Paclitaxel (PTX). Images were acquired every 10 min 
for 24 h. Individual cells were followed manually and scored for defects in mitosis including 
mitotic slippage/polynucleation (MS/PN), micronuclei formation (G1/MN), mitotic slippage (MS) 
or cell death during mitosis (DiM). Representative experiment shown. 
c) Quantification of the time in mitosis of Pol δ replacement-H2B-GFP cells induced with 10 
ng/ml doxycycline for 4 days prior to treatment with 1 nM Vincristine or 20 nM CENP-Ei. 
Individual cells shown from a representative experiment, horizontal line indicates the mean. 
Statistical testing performed using unpaired t-test (ns, not significant). 
d) Mechanism of action of TH588. We propose MTH1 inhibition during S phase does not cause 
replication stress is related to overall low ROS levels also in cancer cells. Prolonged mitotic 
arrest causes mitophagy and ROS (28), likely above physiological levels (dotted line). We 
propose TH588 is causing ROS because of mitotic arrest mediated by directly interfering with 
tubulin polymerization or breaking MTH1-tubulin interactions. Through MTH1 inhibition, TH588 
prevents 8-oxodGTP sanitization resulting in 8-oxodG incorporation into DNA during mitotic 
replication. We speculate cancer-specific toxicity of TH588 is related to replication stress 
associated in cancer, likely triggering mitotic replication, i.e., repair synthesis of under 
replicated regions.  
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